Ascentage Pharma Grp International

Ascentage Pharma Group International reported first-half 2026 revenue of $44.5 million, up 29.3% on a constant-currency basis from $32.6 million a year earlier, driven by $41.6 million in product sales. The company ended the period with $279.4 million in cash and reaffirmed its runway through the end of 2027. Research and development expense rose to $102.8 million from $73.8 million, while selling and distribution expense increased to $33.4 million from $19.2 million, reflecting investment in global registrational studies and commercial build-out. Management said operating expenses have peaked and that existing cash should support enrollment completion, data generation, and multiple anticipated new drug application filings. The company is advancing nine registrational trials, including four cleared by both the U.S. FDA and the European Medicines Agency, and expects to potentially file as many as three NDAs in the second half of 2027.

Ascentage Pharma Group International has appointed Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer. Dr. Miyara will lead global business development, while Mr. Ziegler will oversee commercialization in the United States and other markets outside China, both reporting to Chairman and CEO Dajun Yang. Dr. Miyara brings over 20 years of oncology business development experience from roles at IO Biotech, Ipsen, Pfizer, ImClone Systems, and Eli Lilly. Mr. Ziegler has more than 25 years of commercial leadership experience from Amgen, Gilead Sciences, Iovance Biotherapeutics, and Geron. The appointments create dedicated leadership for Ascentage Pharma's own US commercial organization and its global business development program as the company advances multiple global registrational Phase III trials.

Oppenheimer initiated coverage of Ascentage Pharma Group International with an Outperform rating and a $45 price target, citing recent clinical presentations and a strong cash position. The firm highlighted two oral presentations on olverembatinib at ASCO and early clinical findings from APG-115, while noting the company's $353 million in cash is expected to fund operations through 2027. Separately, Ascentage announced that seventeen clinical updates from its core programs were presented at the EHA2026 Congress, including data on olverembatinib and lisaftoclax across multiple hematologic malignancies. Olverembatinib showed sustained activity in chronic myeloid leukemia and potential in Philadelphia chromosome-positive acute lymphoblastic leukemia, while lisaftoclax data provided insights into treatment strategies for CLL/SLL and myeloid neoplasms.